• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Mainz BioMed NV

    < Previous 1 2 Next >
    Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers DGX MYNZ
    Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Announces Stock Split
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ TMO
    Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Provides Half Year 2024 Corporate Update
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Reports Results of 2024 Annual General Meeting
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Reports Full Year 2023 Financial Results
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    Mainz Biomed Provides Year-End Corporate Review 2023
    From Mainz BioMed NV
    Via GlobeNewswire
    Tickers MYNZ
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.